Nicox to present at the Cantor Fitzgerald 2017 Global Healthcare Conference
September 19, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Michele Garufi, Chairman and Chief Executive Officer of Nicox, will present at the Cantor Fitzgerald 2017 Global Healthcare Conference on Tuesday, September 26th, 2017 at 1:05 p.m. Eastern Time.  The conference is being held at the InterContinental New York Barclay Hotel. The presentation will be available on Nicox website (www.nicox.com) in "Presentations & Events".
About Nicox
Nicox S.A. is an international ophthalmic company developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has one product at the review stage with the U.S. Food and Drug Administration (FDA), VYZULTATM (ophthalmic solution of latanoprostene bunod), 0.024%, licensed worldwide to Bausch + Lomb, and one product with an approved NDA, ZERVIATETM (cetirizine ophthalmic solution) 0.24%.  In addition its promising drug-candidate pipeline includes a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds, as well as repurposing of existing molecules with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co   Hugo Solvet   Paris, France Invest Securities   Martial Descoutures   Paris, France Gilbert Dupont   Damien Choplain   Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Upcoming financial and business conferences
November 23-24  Actionaria   Paris, France
Contacts
Nicox Gavin Spencer, Executive Vice President Corporate Development T +33 (0)4 97 24 53 00 [email protected]
Investor Relations Europe Nicox Corporate Communications Department T +33 (0)4 97 24 53 00 [email protected]	Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 [email protected]
United States Argot Partners Melissa Forst T +1 (212) 600-1902 [email protected]	France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 [email protected]
	United States Argot Partners Eliza Schleifstein T +1 (917) 763-8106 [email protected]
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99